The global cancer cell therapy market was estimated to be valued at US$ 8,525.5 million in 2022 and is expected to exhibit a CAGR of 8.20% over the forecast period 2023-2030.
Market Overview
Cancer cell therapy involves genetically modifying immune cells like T-cells to recognize and kill cancer cells. These therapies have shown promising results in treating hematological malignancies and solid tumors. They provide targeted treatment options with minimal side effects compared to conventional therapies like chemotherapy.
Market Key Trends
One of the key trends in the cancer cell therapy market is the growing development of CAR T-cell therapies. Chimeric antigen receptor (CAR) T-cell therapy involves extracting a patient's T cells and modifying them in the lab to recognize antigens on cancer cells. These engineered T cells are then infused back into the patient to target and kill cancer cells. CAR T-cell therapies against CD19 antigen have shown high remission rates in blood cancers like leukemia and lymphoma. Major players are investing in developing CAR T therapies for solid tumors which have greater market potential.
Segment Analysis
The cancer cell market is segmented into exosomes, small extracellular vesicles, extracellular matrix vesicles, microvesicles and apoptotic bodies. The exosomes segment dominated the market in 2022 and is expected to remain dominant during the forecast period. Exosomes are actively secreted vesicles that are 40–100 nm in size and carry membrane and intracellular proteins as well as transcripts from donor cells to recipient cells. Exosomes can travel to nearby or distant target cells and deliver biomolecules to impact target cell functions. They exhibit strong potential for applications in diagnostics, disease monitoring and therapeutics.
Key Takeaways
The Global Cancer Cell Market Size is expected to witness high growth, exhibiting CAGR of 8.20% over the forecast period, due to increasing prevalence of cancer worldwide. According to WHO, cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2022.
Regional analysis
North America dominated the global cancer cell market in 2022 with a revenue share of over 40%, due to presence of advanced healthcare facilities and significant research expenditure. Asia Pacific is anticipated to grow fastest at a CAGR of 10.5% during 2022-2030, fueled by rising healthcare spending, growing generic drugs market, and expanding healthcare access in China and India.
Key players
Key players operating in the cancer cell market are Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare. These market players are focusing on new product launches, acquisitions, and collaborations to strengthen their market positions.
